Impact Factor
7.883
Call For Paper
Volume 12 Issue 07
July 2026
Download Paper Format
Copyright Form
Author(s)
Shubham jogdande Mascarenhas Maxwell Santosh Waghmare Ashwini Andhale | Dr. H.V Kamble
Abstract
The Identification Of Anaplastic Lymphoma Kinase (ALK) Rearrangements In 2-5% Of Non-small Cell Lung Cancer (NSCLC) Patients Led To The Rapid Clinical Development Of Tyrosine Kinase Inhibitors. Anaplastic Lymphoma Kinase (ALK), A Tyrosine Kinase Has Attra
Keywords
ALK
NSCLC
ALCL
ALK Inhibitors
Crizotinib.
Paper ID
IJSARTV7I1150773
Publication Date
November 10, 2021
Research Area
SCIENCE